MTPConnect has announced that 16 researchers, clinicians and professionals from the medical technology, biotechnology and pharmaceutical sector have secured industry placements under the Researcher Exchange and Development within Industry (REDI) fellowship program.
The new fellows will be working for up to 13 months with companies based in Australia, the US, the UK and Europe.
The REDI fellowship program provides financial support to medical technology and pharmaceutical companies to bring talent in-house to work on priority research projects.
MTPConnect CEO Stuart Dignam said, “Our congratulations to these 16 new fellows who are doing crucial work in our sector for patients – and to the companies at home and abroad who are sponsoring them.
“We are delighted that so many companies, from CSL, Astra Zeneca, Stryker and Penumbra to GE Healthcare Australia, Seer Medical and SpeeDx, have seized the opportunities provided by our highly regarded REDI Fellowship program.
“The fellowships are industry-focused, providing research-intensive companies with the opportunity to access academics and clinicians for distinct projects involving discovery, translation and commercialisation and, in doing so, driving greater collaboration between industry and research.
“With these new fellows selected, the REDI Fellowship program has seen total funding of $8.15 million awarded to 47 Fellows, exceeding our expectations – a fantastic and game-changing result for the MTP sector in Australia."